The Trump administration is touting its efforts to increase generic competition as a key achievement of its push to lower drug prices, but Chip Davis, the head of the generic lobby, tells Inside Health Policy that simply increasing the number of generics approved isn't enough to lower prices. The group tells IHP that 45 percent of its members’ newly approved generic applications aren't launching, and other members are discontinuing product lines because of declining reimbursement. Generic drug...